Rabies vaccine inactivated (VRVg) - Sanofi

Drug Profile

Rabies vaccine inactivated (VRVg) - Sanofi

Alternative Names: Purified Vero Rabies Vaccine - Sanofi; Rabies VRVg; VerorabVax

Latest Information Update: 18 Feb 2016

Price : $50

At a glance

  • Originator sanofi-aventis
  • Developer Sanofi
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Rabies

Most Recent Events

  • 31 Dec 2015 Sanofi completes a phase II trial for Rabies (prevention) in USA (NCT01784874)
  • 19 Mar 2015 No recent reports on development identified - Phase-II for Rabies (Prevention) in India (IM)
  • 01 Sep 2014 Sanofi completes a phase II trial in Rabies (post-exposure prevention) in USA (NCT01877395)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top